Boston Scientific (BSX) Consolidated Net Income (2009 - 2026)

Boston Scientific has disclosed Consolidated Net Income across 18 years of filings, most recently posting $905.0 million for Q2 2026.

• In Q2 2026, Consolidated Net Income rose 13.84% year-over-year to $905.0 million; the TTM figure through Jun 2026 stood at $3.7 billion (up 46.88% YoY), while the FY2025 annual figure was $2.9 billion, up 56.66% from the prior year.
• Consolidated Net Income came in at $905.0 million for Q2 2026 at Boston Scientific, down from $1.3 billion in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $1.3 billion in Q1 2026 to a low of $111.0 million in Q1 2022.
• Average Consolidated Net Income over 5 years is $515.2 million, with a median of $498.5 million recorded in 2023.
• Year-over-year, Consolidated Net Income slumped 67.45% in 2022 and soared 257.45% in 2023.
• Over 5 years, Consolidated Net Income stood at $141.0 million in 2022, then soared by 257.45% to $504.0 million in 2023, then advanced by 11.51% to $562.0 million in 2024, then grew by 19.22% to $670.0 million in 2025, then surged by 35.07% to $905.0 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were $905.0 million in Q2 2026, $1.3 billion in Q1 2026, and $670.0 million in Q4 2025.